GeneSoft Factive Label Should Discourage Prolonged Use, FDA Cmte. Says
Executive Summary
GeneSoft's Factive (gemifloxacin) labeling should recommend against exceeding the initial five- or seven-day course of treatment for acute bacterial exacerbation of chronic bronchitis and community-acquired pneumonia, members of FDA's Anti-Infective Drugs Advisory Committee said March 4
You may also be interested in...
GeneSoft Factive Surveillance Program Will Track Appropriate Prescribing
GeneSoft will track Factive antibiotic prescribing patterns to determine whether labeling adequately promotes short-term use of the drug
GeneSoft Factive Surveillance Program Will Track Appropriate Prescribing
GeneSoft will track Factive antibiotic prescribing patterns to determine whether labeling adequately promotes short-term use of the drug
Factive launch by year-end
GeneSoft will launch Factive (geminfloxacin) in late 2003 after FDA approval April 4 for mild to moderate community-acquired pneumonia and acute bacterial exacerbation of chronic bronchitis. The indication follows FDA's Anti-Infective Drugs Advisory Committee recommendation (1"The Pink Sheet" March 10, p. 11)...